Non-Hodgkin Lymphoma (NHL) Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Chemotherapy, Immunotherapy), By Non-Hodgkins Lymphoma Type (B-cell Lymphoma, T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region Forecast 2019-2030

Non-Hodgkin Lymphoma Treatment Market size was valued at US$ 478.90 million in 2023 and is poised to grow at a significant CAGR of 7.25% from 2024-2030. Non-Hodgkin lymphoma is caused by a combination of factors including age, gender, exposure to chemicals such as benzene and pesticides, a compromised immune system, and chemical exposure. Over the forecast period, increased awareness of cancer diagnosis and treatment, as well as government intervention with various cost-effective policies, are likely to enhance the Non-Hodgkins Lymphoma (NHL) market. Despite the fact that numerous medications are available for NHL, none of them are effective at the end stage, which may limit the growth of the market throughout the projection period.

Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this.

Non-Hodgkins Lymphoma (NHL) is a kind of cancer caused by aberrant B or T lymphocyte and leukocyte function. These lymphomas typically develop in the bone marrow, lymph nodes, spleen, blood, and other lymphatic organs. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Key Developments

In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.